In an adult with moderate‑to‑severe obsessive‑compulsive disorder (Y‑BOCS > 16) refractory to SSRI therapy and cognitive‑behavioral therapy, is NAD+ therapy appropriate and what experimental regimen should be used?

NAD+ Therapy is NOT Appropriate for Treatment-Refractory OCD

NAD+ therapy has no established role in the treatment of obsessive-compulsive disorder and should not be used. There is zero evidence supporting its efficacy, safety, or appropriate dosing for OCD, and it does not appear in any evidence-based treatment guidelines for this condition.

What You Should Do Instead

For an adult with moderate-to-severe OCD (Y-BOCS > 16) refractory to SSRI and CBT, the evidence-based approach is:

First: Verify True Treatment Resistance

Ensure the patient has received:

• At least 3 adequate SSRI trials (8-12 weeks each at maximum tolerated doses—higher than used for depression) 11
• At least one trial of clomipramine (often more effective than SSRIs, though less tolerable) 11
• Adequate CBT with exposure and response prevention (ERP): minimum 20 hours of OCD-specific therapy with homework compliance 11

Second: Evidence-Based Augmentation Strategies

Strongest evidence supports:

1. Augment current SSRI with CBT/ERP if not already optimized—this combination shows larger effect sizes than antipsychotic augmentation 1

2. Antipsychotic augmentation: Add low-dose atypical antipsychotic (risperidone, aripiprazole, quetiapine) to ongoing SSRI therapy 12

3. Switch to clomipramine or add clomipramine to fluoxetine (one trial showed fluoxetine plus clomipramine superior to fluoxetine plus quetiapine) 1

4. Glutamatergic agents: Consider memantine, N-acetylcysteine, or topiramate as augmentation 13

Third: Advanced Interventions for Highly Refractory Cases

If the above strategies fail after 5+ years of severe symptoms:

• Intensive CBT protocols: Multiple daily sessions over days to weeks, often inpatient 11
• Repetitive transcranial magnetic stimulation (rTMS) 24
• Deep brain stimulation (DBS): Requires independent confirmation of treatment refractoriness, Y-BOCS ≥28, age 18-75, and careful patient selection 152

Critical Caveats

Do not pursue experimental therapies like NAD+ when evidence-based options remain untried. The drug label evidence provided 66 pertains to metronidazole (an antibiotic), not NAD+, and mentions NAD+ only in the context of laboratory test interference—it has no therapeutic indication for OCD.

Recent research 3 describes pharmacological intensification strategies (supratherapeutic SSRI dosing, dual SSRI therapy, complex augmentation) used in tertiary centers, but these are experimental, high-risk approaches requiring specialized monitoring for serotonin toxicity and cardiac complications. They should only be considered after exhausting guideline-recommended treatments.

The evidence is unequivocal: SSRIs, clomipramine, CBT/ERP, and their combinations remain the foundation of OCD treatment 1111127. Approximately 50% of patients fail first-line treatment 11, but systematic application of evidence-based augmentation strategies offers meaningful symptom reduction before considering experimental or invasive interventions.